KLK3 and prostate carcinoma: Serum proteomics could distinguish prostate cancer with 95% sensitivity, even when PSA levels were in an indeterminate range (4–10 ng/mL).Test had a high clinical relevance as a complement to physical exams, imaging, and serum PSA levels.